Literature DB >> 10329967

TNF-alpha pretreatment prevents subsequent activation of cultured brain cells with TNF-alpha and hypoxia via ceramide.

I Ginis1, U Schweizer, M Brenner, J Liu, N Azzam, M Spatz, J M Hallenbeck.   

Abstract

We have developed a cellular model in which cultured astrocytes and brain capillary endothelial cells preconditioned with tumor necrosis factor-alpha (TNF-alpha) fail to upregulate intercellular adhesion molecule-1 (ICAM-1) protein (80% inhibition) and mRNA (30% inhibition) when challenged with TNF-alpha or exposed to hypoxia. Inasmuch as ceramide is known to mediate some of the effects of TNF-alpha, its levels were measured at various times after the TNF-alpha preconditioning. We present evidence for the first time that, in normal brain cells, TNF-alpha pretreatment causes a biphasic increase of ceramide levels: an early peak at 15-20 min, when ceramide levels increased 1.9-fold in astrocytes and 2.7-fold in rat brain capillary endothelial cells, and a delayed 2- to 3-fold ceramide increase that occurs 18-24 h after addition of TNF-alpha. The following findings indicate that the delayed ceramide accumulation results in cell unresponsiveness to TNF-alpha: 1) coincident timing of the ceramide peak and the tolerance period, 2) mimicking of preconditioning by addition of exogenous ceramide, and 3) attenuation of preconditioning by fumonisin B1, an inhibitor of ceramide synthesis. In contrast to observations in transformed cell lines, the delayed ceramide increase was transient and did not induce apoptosis in brain cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329967     DOI: 10.1152/ajpcell.1999.276.5.C1171

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

Review 1.  Toll-like receptor signaling in endogenous neuroprotection and stroke.

Authors:  B J Marsh; R L Williams-Karnesky; M P Stenzel-Poore
Journal:  Neuroscience       Date:  2008-08-12       Impact factor: 3.590

2.  Ceramide and mitochondria in ischemic brain injury.

Authors:  Sergei A Novgorodov; Tatyana I Gudz
Journal:  Int J Biochem Mol Biol       Date:  2011-11-25

3.  Lactosylceramide Mediates the Expression of Adhesion Molecules in TNF-α and IFNγ-stimulated Primary Cultured Astrocytes.

Authors:  Jin-Koo Lee; Jin-Kyu Kim; Soo-Hyun Park; Yun-Beom Sim; Jun-Sub Jung; Hong-Won Suh
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

Review 4.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

Authors:  Bolanle M Famakin
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

5.  Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-α.

Authors:  Woldeab B Haile; Jialing Wu; Ramiro Echeverry; Fang Wu; Jie An; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

6.  Opposing effects of proteasomes and lysosomes on LIFR: modulation by TNF.

Authors:  Chuanhui Yu; Abba J Kastin; Hong Tu; Weihong Pan
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

7.  Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells.

Authors:  Junfei Jin; Qi Hou; Thomas D Mullen; Youssef H Zeidan; Jacek Bielawski; Jacqueline M Kraveka; Alicja Bielawska; Lina M Obeid; Yusuf A Hannun; Yi-Te Hsu
Journal:  J Biol Chem       Date:  2008-08-01       Impact factor: 5.157

Review 8.  Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.

Authors:  Brenda J Marsh; Mary P Stenzel-Poore
Journal:  Curr Opin Pharmacol       Date:  2007-11-05       Impact factor: 5.547

Review 9.  Tumor necrosis factor and stroke: role of the blood-brain barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Prog Neurobiol       Date:  2007-08-06       Impact factor: 11.685

Review 10.  Ceramide and mitochondria in ischemia/reperfusion.

Authors:  Sergei A Novgorodov; Tatyana I Gudz
Journal:  J Cardiovasc Pharmacol       Date:  2009-03       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.